Reference number(s)
5078-H

Quantity Limit Criteria
Antiviral For The Treatment Of Covid-19

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Lagevrio	molnupiravir

Uses

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product Lagevrio for treatment of adults with mild-to-moderate coronavirus disease 2019 (COVID-19):

- who are at high risk for progression to severe COVID-19, including hospitalization or death.
- for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

Limitations of Use

- Lagevrio is not authorized for use in patients who are less than 18 years of age.
- Lagevrio is not authorized for initiation of treatment in patients hospitalized due to COVID-19. Benefit of treatment with Lagevrio has not been observed in subjects when treatment was initiated after hospitalization due to COVID-19.
- Lagevrio is not authorized for use for longer than 5 consecutive days.
- Lagevrio is not authorized for pre-exposure or post-exposure prophylaxis for prevention of COVID-19.

Initial Limit Quantity

This drug is for short-term acute use.

Drug	Limit
Lagevrio (molnupiravir) 200 mg capsule	40 capsules / 30 days

References

1. Lagevrio [Emergency Use Authorization Fact Sheet for Healthcare Providers]. Rahway, NJ: Merck Sharp & Dhome LLC; June 2024.
2. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed August 5, 2024.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 08/05/2024).

Document History

Written by: UM Development (VLS)

Date Written: 12/2021

Revised: VLS 11/2022 (updated document title), 11/2023 (no clinical changes), 08/2024 (no clinical changes)

Reviewed: Medical Affairs: (CHART) 12/01/2022, 11/30/2023, 08/29/2024

External Review: 12/2021, 02/2023, 02/2024, 12/2024